Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

Elizabeth K. O'Donnell, MD, Jacob P. Laubach, MD, Andrew J. Yee, MD, Carol A. Huff, MD, Frank G. Basile, MD, Philip M. Wade, Jr., MD, Claudia E. Paba-Prada, MD, Irene M. Ghobrial, MD, Robert L. Schlossman, MD, Nicole R. Couture, BSN, RN, Lauren Doherty, Hannah Lyons, Caroline English, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Noopur S. Raje, MD

Blood (2015) 126 (23): 4217.

https://doi.org/10.1182/blood.V126.23.4217.4217

Published: 2015

Journal Articles

Genetic Susceptibility Markers of Multiple Myeloma in African-Americans

Kristin A Rand, PhD, M.P.H., Chi Song, M.S., Amie E. Hwang, PhD, M.P.H., Carol A. Huff, MD, Leon Bernal-Mizrachi, MD, Michael H Tomasson, MD, Sikander Ailawadhi, MD, David J. Van Den Berg, PhD, Xin Sheng, PhD, John J. Graff, PhD, M.S., David V. Conti, PhD, Todd Zimmerman, MD, Edward Peters, D.MD S.M, Sc.D., Seema Singhal, MD, Cathryn H. Bock, PhD, Karen Pawlish, M.P.H., Graham A Colditz, MD, Dr.PH., Xin Sheng, PhD, Alexander Stram, M.S., Sara S. Strom, PhD, Benjamin Rybicki, PhD, Rick Kittles, PhD, Howard Terebelo, DO, Janet Stanford, PhD, MPH, Phyllis J. Goodman, PhD, Sonja I Berndt, PhD, John Carpten, PhD, Anselm JM Hennis, MSc,PhD MRCP, FRCP, Lisa Chu, PhD, M.P.H., Graham Casey, PhD, W R Driver, MSPH, Eric A. Klein, MD, M. Christina Leske, MD MPH, Esther John, PhD, Adam Bryant Murphy, MD, Christine Neslund-Dudas, PhD, Victoria L. Stevens, PhD, Curtis Pettaway, MD, Wei Zheng, MD PhD MPH, Suh-Yuh Wu, M.A., John Witte, PhD, Siqun Lilly Zheng, MD, Jianfeng Xu, MD,Dr.PH, Nikhil C. Munshi, MD, Ann Hsing, PhD, Sue Ingles, PhD, Jayesh Mehta, MD, Lisa B. Signorello, PhD, Stephen Jacob Chanock, MD, Barbara Nemesure, PhD, Ann M Mohrbacher, MD, Nalini Janakiraman, MD, William J Blot, MD, Brian E. Henderson, MD, Laurence N. Kolonel, MD PhD, Kenneth C. Anderson, MD, Brian C-H Chiu, PhD, Jeffrey Zonder, MD, Robert Z. Orlowski, PhD MD, Sagar Lonial, MD, Daniel O. Stram, PhD, Christopher Haiman, Sc.D., Wendy Cozen, DO, MPH

Blood (2014) 124 (21): 2030.

https://doi.org/10.1182/blood.V124.21.2030.2030

Published: 2014

Journal Articles

A Phase I Study of An Oral Hedgehog Pathway Antagonist, BMS-833923, in Patients with Relapsed or Refractory Multiple Myeloma,

Carol A. Huff, MD, Swaminathan Padmanabhan, MD, Kevin R. Kelly, MD, George Somlo, MD, Luis Camacho, MD, MPH, Jeffrey Zonder, MD, Bruce Fischer, MD, Lixin Lang, Steven Zhang, Toni Gestone, Kelly L. Bennett

Blood (2011) 118 (21): 3993.

https://doi.org/10.1182/blood.V118.21.3993.3993

Published: 2011

Journal Articles

Phase I/II Study of Marrow Infiltrating Lymphocytes (MILs) Generates Measurable Myeloma-Specific Immunity in the Autologous Stem Cell Transplant (SCT) Setting

Kimberly Noonan, MPH, Carol A. Huff, MD, Janice M Davis Sproul, MAS, MT(ASCP), SBB, Mario Victor M Lemas, PhD, Lakshmi Rudraraju, MS, Leo Luznik, Jonathan Powell, MD, PhD, Javier Bolaños-Meade, Jeffrey Bitzan, MT, Susan Fiorino, MT(ASCP), William Matsui, MD, Richard J. Jones, MD, Ivan M. Borrello, MD

Blood (2011) 118 (21): 997.

https://doi.org/10.1182/blood.V118.21.997.997

Published: 2011

Journal Articles

Bortezomib and Thalidomide, a Steroid Free Regimen in Newly Diagnosed Patients with Multiple Myeloma.

Nilanjan Ghosh, Anna Ferguson, RN, Xiaobu Ye, Carol A. Huff, MD, Ivan M. Borrello, MD

Blood (2009) 114 (22): 2867.

https://doi.org/10.1182/blood.V114.22.2867.2867

Published: 2009

Journal Articles

Lenalidomide Augments Immune Responses to Prevnar Vaccination in Relapsed Myeloma Patients: Implications for Cancer and Infectious Vaccines.

Kimberly Ann Noonan, MPH, BS, Anna Ferguson, RN, Amy Emerling, Lakshmi Rudraraju, M.S., Carol A. Huff, MD, Peter H Schafer, Ivan M. Borrello, MD

Blood (2009) 114 (22): 1864.

https://doi.org/10.1182/blood.V114.22.1864.1864

Published: 2009

Journal Articles

The Immunomodulatory Role of Lenalidomide on Prevnar ® Responses in Patients with Relapsed Multiple Myeloma: A Comprehensive Analysis of the Immune Response

Kimberly Ann Noonan, MPH, BS, Anna Ferguson, RN, Carol A. Huff, MD, Amy Emerling, Stephanie Mgebroff, Rose Wilson, Robert D. Knight, MD, Ivan M. Borrello, MD

Blood (2008) 112 (11): 2772.

https://doi.org/10.1182/blood.V112.11.2772.2772

Published: 2008

Journal Articles

Results of a Phase I Study of GRN163L, a Direct Inhibitor of Telomerase, in Patients with Relapsed and Refractory Multiple Myeloma (MM)

Asher Alban Chanan-Khan, MD, Nikhil C. Munshi, MD, Mohamad A. Hussein, M.D., Laurence Elias, MD, Fabio Benedetti, M.D., Jennifer Smith, Ph.D., Soo-Peang Khor, Ph.D., Carol A. Huff, MD

Blood (2008) 112 (11): 3688.

https://doi.org/10.1182/blood.V112.11.3688.3688

Published: 2008

Journal Articles

Cancer Stem Cell Targeting in Multiple Myeloma by GRN163L, a Novel and Potent Telomerase Inhibitor.

William Matsui, MD, Qiuju Wang, MS, Milada Vala, James P. Barber, Alan Meeker, PhD, Robert Tressler, PhD, Calvin Harley, PhD, Carol A. Huff, MD, B. Douglas Smith, MD, Richard J. Jones, MD

Blood (2006) 108 (11): 2540.

https://doi.org/10.1182/blood.V108.11.2540.2540

Published: 2006

NARROW

A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

Genetic Susceptibility Markers of Multiple Myeloma in African-Americans

A Phase I Study of An Oral Hedgehog Pathway Antagonist, BMS-833923, in Patients with Relapsed or Refractory Multiple Myeloma,

Phase I/II Study of Marrow Infiltrating Lymphocytes (MILs) Generates Measurable Myeloma-Specific Immunity in the Autologous Stem Cell Transplant (SCT) Setting

Bortezomib and Thalidomide, a Steroid Free Regimen in Newly Diagnosed Patients with Multiple Myeloma.

Lenalidomide Augments Immune Responses to Prevnar Vaccination in Relapsed Myeloma Patients: Implications for Cancer and Infectious Vaccines.

The Immunomodulatory Role of Lenalidomide on Prevnar ® Responses in Patients with Relapsed Multiple Myeloma: A Comprehensive Analysis of the Immune Response

Results of a Phase I Study of GRN163L, a Direct Inhibitor of Telomerase, in Patients with Relapsed and Refractory Multiple Myeloma (MM)

Cancer Stem Cell Targeting in Multiple Myeloma by GRN163L, a Novel and Potent Telomerase Inhibitor.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only